The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Impact of Global Geographic Region on Time in Therapeutic Range on Warfarin Anticoagulant Therapy: Data From the ROCKET AF Clinical Trial
Open accessAbstract
Background: Vitamin K antagonist ( VKA ) therapy remains the most common method of stroke prevention in patients with atrial fibrillation. Time in therapeutic range ( TTR ) is a widely cited measure of the quality of VKA therapy. We sought to identify factors associated with TTR in a large, international clinical trial. Methods and Results: TTR (international normalized ratio [ INR ] 2.0 to 3.0) was determined using standard linear interpolation in patients randomized to warfarin in the ROCKET AF trial. Factors associated with TTR at the individual patient level (i‐ TTR ) were determined via multivariable linear regression. Among 6983 patients taking warfarin, recruited from 45 countries grouped into 7 regions, the mean i‐ TTR was 55.2% (SD 21.3%) and the median i‐ TTR was 57.9% (interquartile range 43.0% to 70.6%). The mean time with INR <2 was 29.1% and the mean time with an INR >3 was 15.7%. While multiple clinical features were associated with i‐ TTR , dominant determinants were previous warfarin use (mean i‐ TTR of 61.1% for warfarin‐experienced versus 47.4% in VKA ‐naïve patients) and geographic region where patients were managed (mean i‐ TTR varied from 64.1% to 35.9%). These effects persisted in multivariable analysis. Regions with the lowest i‐ TTR s had INR distributions shifted toward lower INR values and had longer inter‐ INR test intervals. Conclusions: Independent of patient clinical features, the regional location of medical care is a dominant determinant of variation in i‐ TTR in global studies of warfarin. Regional differences in mean i‐ TTR are heavily influenced by subtherapeutic INR values and are associated with reduced frequency of INR testing. Clinical Trial Registration: URL: ClinicalTrials.gov . Unique identifier: NCT 00403767.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Self-citationApixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Fuster, V., Rydén, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.177292 · Cited by 2,805
Self-citationConnolly, S. J., Pogue, J., Eikelboom, J., Flaker, G., Commerford, P., Franzosi, M. G., Healey, J. S., & Yusuf, S. (2008) · Circulation · doi:10.1161/circulationaha.107.750000 · Cited by 870
Cited by
Global epidemiology of atrial fibrillation
Rahman, F., Kwan, G. F., & Benjamin, E. J. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.118 · Cited by 731
Causes of Death in Anticoagulated Patients With Atrial Fibrillation
Gómez-Outes, A., Lagunar-Ruíz, J., Terleira-Fernández, A.-I., Calvo-Rojas, G., Suárez-Gea, M. L., & Vargas-Castrillón, E. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.09.944 · Cited by 264
Goodman (2014) · doi:10.1016/j.jacc.2013.11.013 · Cited by 228
Kite, C., Lahart, I. M., Afzal, I., Broom, D. R., Randeva, H., Kyrou, I., & Brown, J. E. (2019) · Systematic Reviews · doi:10.1186/s13643-019-0962-3 · Cited by 155
Metadata
- Authors
- Singer, D. E., Hellkamp, A. S., Piccini, J. P., Mahaffey, K. W., Lokhnygina, Y., Pan, G., Halperin, J. L., Becker, R. C., Breithardt, G., Hankey, G. J., Hacke, W., Nessel, C. C., Patel, M. R., Califf, R. M., Fox, K. A. A., & ROCKET AF Investigators
- Venue
- Journal of the American Heart Association
- Published
- 2013-01-23
- Volume
- 2
- Issue
- 1
- Pages
- e000067-e000067
- ISSN
- 2047-9980 (ISSN-L)
- OpenAlex
- W2124691949
- Cited by
- 242
- References
- 6
- FWCI
- 17.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of Global Geographic Region on Time in Therapeutic Range on Warfarin Anticoagulant Therapy: Data From the ROCKET AF Clinical Trial. https://app.cochat.ai/papers/10.1161/jaha.112.000067
- The paper
- Singer, D. E., Hellkamp, A. S., Piccini, J. P., Mahaffey, K. W., Lokhnygina, Y., Pan, G., Halperin, J. L., Becker, R. C., Breithardt, G., Hankey, G. J., Hacke, W., Nessel, C. C., Patel, M. R., Califf, R. M., Fox, K. A. A., & ROCKET AF Investigators. (2013). Impact of Global Geographic Region on Time in Therapeutic Range on Warfarin Anticoagulant Therapy: Data From the ROCKET AF Clinical Trial. Journal of the American Heart Association. https://doi.org/10.1161/jaha.112.000067
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.